SAGE-217 15/20 mg Oral Solution + Placebo + SAGE 217 30 mg Capsules
Phase 3Completed 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Postpartum Depression
Conditions
Postpartum Depression
Trial Timeline
Jan 4, 2017 → Dec 11, 2018
NCT ID
NCT02978326About SAGE-217 15/20 mg Oral Solution + Placebo + SAGE 217 30 mg Capsules
SAGE-217 15/20 mg Oral Solution + Placebo + SAGE 217 30 mg Capsules is a phase 3 stage product being developed by Biogen for Postpartum Depression. The current trial status is completed. This product is registered under clinical trial identifier NCT02978326. Target conditions include Postpartum Depression.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02978326 | Phase 3 | Completed |
Competing Products
20 competing products in Postpartum Depression
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Misoprostol + Oxytocin | Cipla | Phase 3 | 77 |
| Quetiapine | AstraZeneca | Phase 2 | 52 |
| Azithromycin + Azithromycin and amoxicillin + Placebo | Merck | Approved | 85 |
| Eptacog alfa (NovoSeven) | Novo Nordisk | Approved | 84 |
| Eptacog alfa (activated) | Novo Nordisk | Pre-clinical | 22 |
| aripiprazole | Bristol Myers Squibb | Phase 3 | 76 |
| fibrinogen concentrate + Placebo | CSL | Phase 1/2 | 40 |
| SAGE-217 + Placebo | Biogen | Phase 3 | 74 |
| Zuranolone | Biogen | Pre-clinical | 20 |
| Zuranolone | Biogen | Pre-clinical | 20 |
| LPCN 1154A + Placebo | Lipocine | Phase 3 | 69 |
| Goserelin 3.6 mg implant + Placebo | Brain Biotech | Pre-clinical | 15 |
| ZULRESSO (brexanolone) injection | Supernus Pharmaceuticals | Pre-clinical | 18 |
| Placebo + SAGE-547 90 μg/kg/h | Supernus Pharmaceuticals | Phase 3 | 72 |
| ZULRESSO® | Supernus Pharmaceuticals | Approved | 80 |
| SAGE-547 | Supernus Pharmaceuticals | Phase 2 | 47 |
| Placebo + SAGE-547 60 μg/kg/h + SAGE-547 90 μg/kg/h | Supernus Pharmaceuticals | Phase 3 | 72 |
| SAGE-547 + Placebo | Supernus Pharmaceuticals | Phase 2 | 47 |
| GH001 | GH Research | Phase 2 | 47 |
| Brexanolone | Brain Biotech | Pre-clinical | 15 |